000590.SZ
古汉医药
SZSE · Healthcare · C 制造业 · CN
CNY 9.05
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 344.1M | 337.7M | 343.2M | 404.6M | 350.5M |
| Cost of Revenue | 193.3M | 186.6M | 182.5M | 192.5M | 171.3M |
| Gross Profit | 150.8M | 151.1M | 160.7M | 212.1M | 179.2M |
| Operating Expenses | |||||
| R&D Expense | 14.2M | 13.9M | 13.2M | 12.8M | 13.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 87.8M | 92.0M | 95.6M | 86.8M | 81.2M |
| Selling & Marketing Expense | 57.5M | 62.1M | 69.4M | 89.8M | 64.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 170.0M | 178.5M | 188.7M | 200.3M | 163.5M |
| Cost and Expenses | 363.3M | 365.1M | 371.2M | 392.8M | 334.9M |
| Operating Income (EBIT) | (42.7M) | (51.2M) | (168.7M) | 20.2M | 22.7M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (41.1M) | (49.6M) | (122.1M) | 29.7M | 21.9M |
| Income Tax Expense | (454.1K) | 485.2K | 5.1M | 4.8M | 3.7M |
| Bottom Line | |||||
| Net Income | (41.1M) | (50.5M) | (125.5M) | 25.2M | 18.1M |
| Earnings from Cont. Ops | (40.6M) | (50.1M) | (127.2M) | 24.9M | 18.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (41.1M) | (50.5M) | (125.5M) | 25.2M | 18.1M |
| Per Share | |||||
| Basic EPS | (CN¥0.17) | (CN¥0.21) | (CN¥0.52) | CN¥0.11 | CN¥0.08 |
| Diluted EPS | (CN¥0.17) | (CN¥0.21) | (CN¥0.52) | CN¥0.11 | CN¥0.08 |
| Revenue Per Share | CN¥1.44 | CN¥1.41 | CN¥1.43 | CN¥1.69 | CN¥1.46 |
| Shares | |||||
| Basic Shares Outstanding | 239.1M | 239.4M | 239.4M | 239.5M | 239.5M |
| Diluted Shares Outstanding | 239.1M | 239.4M | 239.4M | 239.5M | 239.5M |
| Profitability Metrics | |||||
| EBITDA | — | (20.2M) | (141.5M) | 46.5M | 45.0M |
| D&A | — | 31.0M | 27.2M | 26.3M | 22.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026